Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
REDWOOD CITY, Calif., Aug. 09, 2016 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company plans to participate in the Canaccord Genuity 36th Annual Growth Conference in Boston.
Avinger management is scheduled to present on Wednesday, August 10, 2016 at 1:00pm ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular Platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
“Avinger,” “Lumivascular,” “Lightbox,” “Ocelot,” “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
